Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)

Michael Becker

View as an RSS Feed
View Michael Becker's Articles BY TICKER:
  • Medical Advances May Help Improve Psoriasis Outcomes
    on Sun, Nov 11, 2012 • CELG, NVS, IDRA • 3 Comments
  • Thinking Of Spring: Tulips And Cancer Stem Cell Mania
    on Mon, Mar 5, 2012 • ENMD, GERN, IMUC • 2 Comments
  • Rethinking Immunotherapy For Brain Tumors
    on Fri, Feb 24, 2012 • AGEN, CLDX, DNDN • 6 Comments
  • 2011 Review And Outlook For Biotechnology In 2012
    on Wed, Jan 25, 2012 • AKRX, DNDN, MDVN • 2 Comments
  • 2012 Preview: Cancer Immunotherapy Catalysts
    on Thu, Dec 15, 2011 • DNDN, AGEN, CELG • 20 Comments
  • Baker's Dozen Trying To Beat The Odds In Pancreatic Cancer
    on Tue, Oct 25, 2011 • CELG, AMGN, THLD • 6 Comments
  • Adjuvants May Hold Key To Unlocking Cancer Immunotherapy Revolution
    on Tue, Sep 20, 2011 • AGEN, CLDX, IDRA • 12 Comments
  • Advances in Radiation Therapy and Related Cancer Stocks
    on Fri, Jul 29, 2011 • CBLI, AZN • Comment!
  • Cancer Immunotherapy: A Roundtable Discussion
    on Thu, Jun 30, 2011 • BIIB, GNMSY.PK, GSK • 6 Comments
  • 3 Late-Stage Leukemia Company Previews for ASCO 2011
    on Mon, May 9, 2011 • ASTX, CYCC, SNSS • Comment!
  • Similarities Between the First Two Active Immunotherapies in Cancer
    on Wed, Mar 30, 2011 • DNDN, BMY, MDVN • Comment!
  • Ipilimumab Approval Highlights Active Immunotherapy Renaissance
    on Sun, Mar 27, 2011 • BMY, DNDN, CLDX • 13 Comments
  • Earthquake Highlights Opportunity for Treating Radiation Sickness
    on Mon, Mar 14, 2011 • OSIR, CBLI, AMGN • 13 Comments
  • To Partner or Not to Partner: That Is the Question
    on Thu, Mar 10, 2011 • CLDX, PFE, RHHBY.OB • 13 Comments
  • Do Mergers Mean Billions for Biotech?
    on Wed, Feb 16, 2011 • SNY, AMGN, BIIB • 2 Comments
  • Warning Biotech Investors: FDA Advisory Panels' No Means No, Yes Means Maybe
    on Mon, Feb 7, 2011 • OREX, ITMN, MELA • 5 Comments
  • Biotech Merger/Acquisition Activity Mixed During Major Conference
    on Tue, Jan 18, 2011 • CTIC, ACAD, CLSN • 1 Comment
  • Biotech’s Top and Bottom 10 From 2010
    on Thu, Jan 6, 2011 • BTK, NBI, DIA • 3 Comments
  • Drug Development Spotlight: The mTOR's New Clothes?
    on Tue, Nov 23, 2010 • AEZS, PGNX, EXEL • 5 Comments
  • Amgen, Celgene and Novartis in the Fight Against Pancreatic Cancer
    on Tue, Oct 26, 2010 • AAPL, CELG, AMGN • 7 Comments
  • Investment Opportunities in AML Frontline Therapies
    on Tue, Sep 7, 2010 • ASTX, CELG, SGEN • 7 Comments
  • Stem Cell Competition Heating Up
    on Wed, Aug 25, 2010 • GERN, STEM, ASTM • 8 Comments
  • Monoclonal Antibody Companies Command Premiums
    on Mon, Jul 12, 2010 • IMGN, IMMU, MITI • 2 Comments
  • Five Key Factors Weighing on Dendreon
    on Fri, Jul 2, 2010 • DNDN, LLY, SNY • 50 Comments
  • Cyclin-Dependent Cancer Confab Preview
    on Sat, Apr 17, 2010 • CYCC, SNSS, PFE • 1 Comment
  • 7 Companies in the Race to Find Cures for Cancer
    on Thu, Apr 8, 2010 • DNDN, AGEN, VICL • 10 Comments
  • For Biotech in 2010, It's Déjà Vu All Over Again
    on Mon, Mar 8, 2010 • MNKD, ITMN, ALKS • 4 Comments
  • BMT Tandem Meetings Review: Gut Check Time for Graft-Versus-Host Disease Companies
    on Mon, Mar 1, 2010 • OSIR, CELG • Comment!
  • Iron Safety Hits AMAG Pharmaceuticals
    on Thu, Feb 4, 2010 • AMAG, ACT • 6 Comments
  • Biotech Deal Activity Slows - The Pause that Refreshes?
    on Sun, Jan 17, 2010 • CEPH, AMGN, MDT • Comment!
  • Biotech’s 2009 Stealth Small Cap Rally
    on Mon, Jan 4, 2010 • AMGN, BIIB, CELG • 1 Comment
  • Graft-Versus-Host Disease: Failures and Future Opportunities
    on Thu, Dec 10, 2009 • OSIR, CYCC, XOMA • Comment!